Nabi Biopharmaceuticals (NASDAQ:NABI)

CAPS Rating: 4 out of 5

The Company leverage its experience and knowledge in powering the human immune system to develop and market products that target serious medical conditions in the areas of transplantation, infectious disease and hematology/oncology.

Recs

1
Player Avatar hukp (< 20) Submitted: 10/3/2006 2:54:50 PM : Outperform Start Price: $5.69 NABI Score: -78.03

Hired consulting firm to help

Featured Broker Partners


Advertisement